American Journal of Kidney Diseases
Volume 53, Issue 2 , Pages 332-345 , February 2009

Dual Blockade of the Renin-Angiotensin System for Cardiorenal Protection: An Update

  • Mustafa Arıcı, MD

      Affiliations

    • Corresponding Author InformationAddress correspondence to Mustafa Arıcı, MD, Hacettepe Hastanesi, Nefroloji Bolumu, 06100 Sihhiye, Ankara, Turkey
    • ,
  • Yunus Erdem, MD

Received 29 July 2008 ,Accepted 17 November 2008.

References 

  1. Fyhrquist F, Saijonmaa O. Renin-angiotensin system revisited. J Intern Med. 2008;264:224–236
  2. Cushman DW, Cheung HS, Sabo EF. Development and design of specific inhibitors of angiotensin-converting enzyme. Am J Cardiol. 1982;49:1390–1394
  3. Bhardwaj G. How the antihypertensive losartan was discovered. Expert Opin Drug Discov. 2006;1:609–618
  4. Lewington AJ, Arici M, Harris KPG, et al. Modulation of the renin-angiotensin system in proteinuric renal disease: are there added benefits?. Nephrol Dial Transplant. 2001;16:885–888
  5. Wolf G, Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int. 2005;67:799–812
  6. Matchar DB, McCrory DC, Orlando LA, et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med. 2008;148:16–29
  7. Weber MA. New opportunities in cardiovascular patient management: a survey of clinical data on the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Am J Cardiol. 2007;100:45J–52J
  8. Unger T, Stoppelhaar M. Rationale for double renin-angiotensin-aldosterone-system blockade. Am J Cardiol. 2007;100:25J–31J
  9. Cohn JN, Goldman JM. Establishing a new option for target-organ protection: rationale for ARB plus ACE inhibitor combination therapy. Am J Hypertens. 2008;23:248–256
  10. van de Wal RMA, van Veldhuisen DJ, van Gilst WH, et al. Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: controversial or common sense?. Eur Heart J. 2005;26:2361–2367
  11. van de Wal RMA, Plokker HW, Lok DJ, et al. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition. Int J Cardiol. 2006;106:367–372
  12. Huang XR, Chen WY, Truong LD, Lan HY. Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J Am Soc Nephrol. 2003;14:1738–1747
  13. Carey RM. Update on the role of the AT2 receptor. Curr Opin Nephrol Hypertens. 2005;4:67–71
  14. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet. 2000;355:637–645
  15. Doulton TW, He FJ, MacGregor GA. Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension. 2005;45:880–886
  16. Morgan T, Anderson A, Bertram D, MacInnis RJ. Effect of candesartan and lisinopril alone and in combination on blood pressure and microalbuminuria. J Renin Angiotensin Aldosterone Syst. 2004;5:64–71
  17. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. New Engl J Med. 2008;358:1547–1559
  18. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 Guidelines for the management of arterial hypertension. J Hypertens. 2007;25:1105–1187
  19. Cohn JN, Tognoni G Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;365:1667–1675
  20. McMurray JJ, Östergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362:767–771
  21. Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. New Engl J Med. 2003;349:1893–1906
  22. Jneid H, Moukarbel GV, Dawson B, et al. Combining neuroendocrine inhibitors in heart failure: reflections on safety and efficacy. Am J Med. 2007;120:1090.e1–1090.e8
  23. Lakhdar R, Al-Mallah MH, Lanfear DE. Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials. J Card Fail. 2008;14:181–188
  24. Werner C, Baumhakel M, Teo KK, et al. RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection. Clin Res Cardiol. 2008;97:418–431
  25. Mann JFE, Schmieder R, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372:547–553
  26. Sarafidis PA, Bakris GL. Renin-angiotensin blockade and kidney disease. Lancet. 2008;372:511–512
  27. Toto R, Palmer BF. Rationale for combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor treatment and end-organ protection in patients with chronic kidney disease. Am J Nephrol. 2008;28:372–380
  28. Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ. 2000;321:1440–1444
  29. Andersen NH, Poulsen PL, Knudsen ST, et al. Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes. Diabetes Care. 2005;28:273–277
  30. Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet. 2003;361:117–124
  31. Bidani A. Controversy about COOPERATE ABPM trial data. Am J Nephrol. 2006;26:629–632
  32. Kunz R, Wolbers M, Glass T, et al. The COOPERATE trial: a letter of concern. Lancet. 2008;371:1575
  33. MacKinnon M, Shurraw S, Akbari A, et al. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. Am J Kidney Dis. 2006;48:8–20
  34. Kunz R, Friedrich C, Wolbers M, et al. Meta-analysis: Effect of monotherapy and combination therapy with inhibitors of the renin-angiotensin system on proteinuria in renal disease. Ann Intern Med. 2008;148:30–48
  35. Catapano F, Chiodini P, De Nicola L, et al. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression. Am J Kidney Dis. 2008;52:475–485
  36. Parfrey PS. Inhibitors of the renin-angiotensin system: Proven benefits, unproven safety. Ann Intern Med. 2008;148:76–77
  37. Bakris GL, Ruilope L, Locatelli F, et al. Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial. Kidney Int. 2007;72:879–885
  38. Menne J, Farsang C, Deak L, et al. Valsartan in combination with lisinopril versus the respective high dose monotherapies in hypertensive patients with microalbuminuria: the VALERIA trial. J Hypertens. 2008;26:1860–1867
  39. Forclaz A, Maillard M, Nussberger J, et al. Angiotensin II receptor blockade: is there truly a benefit of adding an ACE inhibitor?. Hypertension. 2003;41:31–36
  40. Berl T. Maximizing inhibition of the renin-angiotensin system with high doses of converting enzyme inhibitors or angiotensin receptor blockers. Nephrol Dial Transplant. 2008;23:2443–2447
  41. Department of Veterans Affairs. VA NEPHRON-D Study (CSP#565). http://clinicaltrials.gov/ct2/results?term=NCT00555217Accessed October 12, 2008
  42. Kazi D, Deswal A. Role and optimal dosing of angiotensin-converting enzyme inhibitors in heart failure. Cardiol Clin. 2008;26:1–14
  43. Brown NJ. Aldosterone and end-organ damage. Curr Opin Nephrol Hypertens. 2005;14:235–241
  44. Pitt B, Zannad F, Remme WJ, et al. Randomized Aldactone Evaluation Study Investigators The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709–717
  45. Pitt B, Remme WJ, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–1321
  46. Remuzzi G, Cattaneo D, Perico N. The aggravating mechanisms of aldosterone on kidney fibrosis. J Am Soc Nephrol. 2008;19:1459–1462
  47. Juurlin DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351:543–551
  48. Staessen J, Li Y, Richart T. Oral renin inhibitors. Lancet. 2006;368:1449–1456
  49. Uresin Y, Taylor AA, Kilo C, et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst. 2007;8:190–198
  50. Oparil S, Yarrows SA, Patel S, et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet. 2007;370:221–229
  51. Parving HH, Persson F, Lewis JB, et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358:2433–2446
  52. Birkenhager WH, Staessen JA. Dual inhibition of the renin system by aliskiren and valsartan. Lancet. 2007;370:195–196
  53. Ingelfinger JR. Aliskiren and dual therapy in type 2 diabetes mellitus. N Engl J Med. 2008;358:2503–2505
  54. Gaddam KK, Oparil S. Renin inhibition: should it supplant ACE inhibitors and ARBs in high risk patients?. Curr Opin Nephrol Hypertens. 2008;17:484–490
  55. Azizi M, Linhart A, Alexander J, et al. Pilot study of combined blockade of the renin-angiotensin system in essential hypertensive patients. Hypertens. 2000;18:1139–1147
  56. Stergiou GS, Skeva II, Baibas NM, et al. Additive hypotensive effect of angiotensin-converting enzyme inhibition and angiotensin-receptor antagonism in essential hypertension. Cardiovasc Pharmacol. 2000;35:937–941
  57. Weir MR, Smith DHG, Neutel JM, Bedigian MP. Valsartan alone or with a diuretic or ACE inhibitor as treatment for African American hypertensives: relation to salt intake. Am J Hypertens. 2001;14:665–671
  58. Weir MR, Weber MA, Neutel JM, et al. ACTION Study Investigators Efficacy of candesartan cilexetil as add-on therapy in hypertensive patients uncontrolled on background therapy: a clinical experience trial. Am J Hypertens. 2001;14:567–572
  59. Anan F, Takahashi N, Ooie T, et al. Effects of valsartan and perindopril combination therapy on left ventricular hypertrophy and aortic arterial stiffness in patients with essential hypertension. Eur J Clin Pharmacol. 2005;61:353–359
  60. Petrovic J, Petrovic D, Vukovic N, et al. Ventricular and vascular remodeling effects of the angiotensin II receptor blocker telmisartan and/or the angiotensin-converting enzyme inhibitor ramipril in hypertensive patients. J Int Med Res. 2005;33(suppl 1):39A–49A
  61. McKelvie RS, Yusuf S, Pericak D, et al. The RESOLVD Pilot Study Investigators Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. Circulation. 1999;100:1056–1064
  62. Baruch L, Anand I, Cohen IS, et al. Vasodilator Heart Failure Trial (V-HeFT) Study Group Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Circulation. 1999;99:2658–2664
  63. Hamroff G, Katz SD, Mancini D, et al. Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation. 1999;99:990–992
  64. Murdoch DR, McDonagh TA, Farmer R, et al. ADEPT: addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects. Am Heart J. 2001;141:800–807
  65. Mario Negri Institute for Pharmacological Research. Preventing ESRD in Overt Nephropathy of Type 2 Diabetes (VALID). http://clinicaltrials.gov/ct2/results?term=NCT00494715Accessed October 12, 2008
  66. Nanfang Hospital. Safety of Dual Blockage of Renin-Angiotensin System in Patients With Advanced Renal Insufficiency (SDBRAS). http://clinicaltrials.gov/ct2/results?term=NCT00630708Accessed October 12, 2008
  67. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Boehringer Ingelheim Pharmaceuticals, Merck, Polycystic Kidney Disease Foundation. HALT Progression of Polycystic Kidney Disease (HALT PKD). http://clinicaltrials.gov/ct2/results?term=NCT00283686Accessed October 12, 2008

PII: S0272-6386(08)01750-2

doi: 10.1053/j.ajkd.2008.11.021

American Journal of Kidney Diseases
Volume 53, Issue 2 , Pages 332-345 , February 2009

Article Tools

* Image Usage & Resolution